5th Circ. Revives Unfair Competition Fight Over Arthritis Drug <https://www.law360.com/competition/articles/2324154?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-14&read_main=1&nlsidx=0&nlaidx=3>
By Dorothy Atkins The Fifth Circuit has revived Zyla Life Sciences LLC's lawsuit seeking to block Texas rival Wells Pharma from selling rheumatoid arthritis drug suppositories that aren't U.S. Food and Drug Administration-approved, rejecting Wells Pharma's argument that Zyla's state claims are preempted under federal law and noting that finding otherwise would have "staggering" implications. Opinion attached | Read full article » <https://www.law360.com/competition/articles/2324154?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-14&read_more=1&nlsidx=0&nlaidx=3> | Save to favorites » <https://www.law360.com/competition/articles/2324154?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-14&read_later=1&nlsidx=0&nlaidx=3>
